{
    "clinical_study": {
        "@rank": "97519", 
        "arm_group": [
            {
                "arm_group_label": "cocaine hydrochloride", 
                "arm_group_type": "Experimental", 
                "description": "cocaine hydrochloride"
            }, 
            {
                "arm_group_label": "propranolol", 
                "arm_group_type": "Experimental", 
                "description": "propranolol"
            }, 
            {
                "arm_group_label": "placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "placebo"
            }
        ], 
        "brief_summary": {
            "textblock": "We will develop a procedure for conditioning cue-cocaine associations in human drug users.\n      Next, we will reactivate that learning and intervene pharmacologically to prevent the\n      reconsolidation of cue-drug memories. We hypothesize that a combined behavioral and\n      pharmacological approach will have significant potential for persistently inhibiting\n      relapse."
        }, 
        "brief_title": "Establishing and Eliminating Cue-drug Associations in Human Cocaine Addiction", 
        "condition": "Cocaine Dependent Subjects", 
        "condition_browse": {
            "mesh_term": "Cocaine-Related Disorders"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Age 18 - 50 years\n\n          2. voluntary, written, informed consent\n\n          3. physically healthy by medical history, physical, neurological, ECG, and laboratory\n             examinations\n\n          4. DSM-IV criteria for Cocaine Abuse (305.60) or Cocaine Dependence (304.20)\n\n          5. recent street cocaine use in excess of that administered in the current study\n\n          6. intravenous and/or smoked (crack/freebase) use\n\n          7. positive urine toxicology screen for cocaine\n\n          8. for females, non-lactating, no longer of child-bearing potential (or agree to\n             practice effective contraception during the study), and a negative serum pregnancy\n             (-HCG) test\n\n          9. able to read English and complete study evaluations.\n\n        Exclusion Criteria:\n\n          1. Other drug dependence (except nicotine)\n\n          2. a primary major DSM-IV psychiatric diagnosis (schizophrenia, bipolar disorder, etc.),\n             unrelated to cocaine\n\n          3. a history of significant medical (cardiovascular) or neurological illness (e.g.,\n             prior myocardial infarction, current active symptoms of cardiovascular disease /\n             angina, evidence of cocaine-related cardiovascular symptoms, prior arrythmias of\n             clinical significance, and/or need for cardiovascular resuscitation, neurovascular\n             events such as transient ischemic attacks, stroke, and/or seizures)\n\n          4. current use of psychotropic and/or potentially psychoactive prescription medication\n\n          5. seeking treatment for drug abuse/dependence\n\n          6. those having contraindications to beta-blocker administration, including diagnoses of\n             asthma, bronchitis, emphysema, or a history of adverse reactions to beta-blockers\n             (including propranolol), as well as those with bradycardia and/or first-degree or\n             greater heart block by ECG"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "50 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "24", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "October 17, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01978457", 
            "org_study_id": "1104008404"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "cocaine hydrochloride", 
                    "propranolol", 
                    "placebo"
                ], 
                "intervention_name": "cocaine hydrochloride", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "cocaine hydrochloride", 
                    "propranolol", 
                    "placebo"
                ], 
                "intervention_name": "propranolol", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "cocaine hydrochloride", 
                "intervention_name": "placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Cocaine", 
                "Propranolol"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "October 31, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "New Haven", 
                    "country": "United States", 
                    "state": "Connecticut", 
                    "zip": "06519"
                }, 
                "name": "Connecticut Mental Health Center"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "3", 
        "official_title": "Establishing and Eliminating Cue-drug Associations in Human Cocaine Addiction", 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "August 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Data on cocaine self-administration (total number of responses) will be checked for normality prior to analysis using Kolmogorov-Smirnov statistics and normal probability plots. Data that is not normally distributed will be log transformed. If it remains highly skewed after transformation, it will be analyzed using non-parametric approaches (e.g., a non-parametric, ANOVA-Type Statistic). Normally distributed data will be analyzed employing a mixed model design, 3-way ANOVA with co-factors of placebo vs propranolol (between subjects), non-cocaine predicting cues vs. cocaine predicting cues (within subjects) and non-reactivated cocaine cues vs. reactivated cocaine cues (within subjects).", 
            "measure": "Total number of patient controlled analgesic (PCA) pump activations (responses)", 
            "safety_issue": "No", 
            "time_frame": "3 days"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01978457"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Yale University", 
            "investigator_full_name": "Robert Malison", 
            "investigator_title": "Principal Investigator", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "source": "Yale University", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Yale University", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "October 2012", 
        "study_design": "Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science", 
        "study_type": "Interventional", 
        "verification_date": "October 2013"
    }
}